- Combination chemotherapy with cytosine arabinoside and idarubicin for acute myelogenous leukemia
-
Shin HC, Jung CW, Lee JH, Lee JA, Yang SH, Leem YH, Park SY, Kim BK, Kim NK
- KMID: 1688361
- Korean J Hematol.
- 1993 Nov;28(2):247-255.
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Renission induction chemotherapy with idarubicin and cytosine arabinoside for the patients with acute myelogenous leukemia
-
Jin JY, Uhm HS, Jeon DS, Lee JW, Han CH, Min WS, Park CW, Kim CC, Kim DJ, Choi WK, Kim HK
- KMID: 2252478
- Korean J Hematol.
- 1991 Oct;26(2):281-287.
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Effects of Induction Chemotherapy with BHAC Plus Idarubicin on Long-term Survival for Patients with Acute Myelogenous Leukemia according to Different Postremission Strategies
-
Kim CC, Lee JW, Kim HJ, Kim KW, Park SJ, Suh JG, Min CK, Eom HS, Hong YS, Min WS, Shin WS, Kim DJ
- KMID: 2083381
- Korean J Hematol.
- 1999 May;34(2):317-325.
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Improvement of Induction Remission Rate by Modifying the Dose of Idarubicin for Relapsed Childhood Acute Lymphoblastic Leukemia
-
Yoon JH, Park JA, Kim EK, Kang HJ, Shin HY, Ahn HS
- KMID: 1779131
- J Korean Med Sci.
- 2009 Apr;24(2):281-288.
- doi: 10.3346/jkms.2009.24.2.281
Relapse is the major cause of treatment failure in acute lymphoblastic leukemia (ALL), yet there is no established treatment for relapsed ALL. To improve the induction remission rate, we modified... -
- CITED
-
- Close
- SHARE
-
- Close
- Comparison between Daunorubicin and Idarubicin in Acute Myelocytic Leukemia Induction Therapy and the Analysis of Prognostic Factors
-
Kim HJ, Lee HG, Ahn BH, Kim WS, Yoon SS, Kang WK, Park K, Yang YS, Kim SH, Kim S, Park CH
- KMID: 2143363
- Korean J Hematol.
- 1999 Aug;34(3):396-402.
BACKGROUND: Anthracycline is the most important chemotherapy drug of acute myelocytic leukemia (AML). It has been reported that idarubicin could have better complete remission (CR) rate than daunorubicin. However, it... -
- CITED
-
- Close
- SHARE
-
- Close
- Cytarabine Plus Daunorubicin or Idarubicin as Induction Chemotherapy for the Patients with De novo Acute Myelogenous Leukemia
-
Ahn JH, Lee JH, Lee KH, Bahng H, Lee JH, Lee JS, Kim SH, Kim WK
- KMID: 2143343
- Korean J Hematol.
- 2000 Nov;35(3-4):214-221.
BACKGROUND: The combination of cytarabine plus anthracycline has been considered standard chemotherapy for acute myelogenous leukemia (AML). We retrospectively analyzed the treatment results of the patients with de novo AML... -
- CITED
-
- Close
- SHARE
-
- Close
- A Case of Acute Myelogenous Leukemia during Pregnancy
-
Lee JG, Yang SH, Kim HT
- KMID: 1906184
- J Korean Cancer Assoc.
- 1997 Jun;29(3):516-521.
The incidence of acute leukemia in pregnancy is rare. The treatment of acute leukemia during pregnancy is complicated and therapeutic options must be made with each individual patient. Complete remission... -
- CITED
-
- Close
- SHARE
-
- Close
- Cytarabine and Idarubicin Induction Chemotherapy in Patients with Acute Myelogenous Leukemia
-
Lee JS, Bang SM, Ju KT, Ahn JY, Cho YK, Cho EK, Shin DB, Lee JH
- KMID: 1832117
- Korean J Hematol.
- 2001 May;36(2):129-135.
BACKGROUND: About 60~80% of previously untreated patients with acute myelogenous leukemia (AML) achieve complete remission (CR) when treated with cytarabine and anthracycline. Anthracycline is one of the most important chemotherapeutic... -
- CITED
-
- Close
- SHARE
-
- Close
- Induction Chemotherapy with BH-AC, Idarubicin, and 6-Thioguanine in Childhood Acute Myelogenous Leukemia
-
Han HJ, Kang HJ, Lee JA, Choi HS, Park HJ, Seong KW, Yoo ES, Shin HY, Ahn HS
- KMID: 2335317
- J Korean Pediatr Soc.
- 1998 Feb;41(2):209-215.
PURPOSE: We have undertaken this study to evaluate the effects of induction chemotherapy involving BH-AC, idarubicin, and 6-thioguanine (6-TG). METHODS: BH-AC 300mg/m2/day was administered intravenously over three hours for seven... -
- CITED
-
- Close
- SHARE
-
- Close
- Comparison of Combination Induction Chemotherapy using Idarubicin Plus either Enoron(r) or Sunrabin(r) in Adult Patients with Acute Myeloid Leukemia
-
Kim HJ, Min WS, Park YH, Kim YJ, Lee S, Kim DW, Lee JW, Kim CC
- KMID: 1637292
- Korean J Hematol.
- 2004 Mar;39(1):10-15.
BACKGROUND: To evaluate the effects and toxicity of combination chemotherapy using idarubicin (IDA) plus BH-AC as an induction regimen, we studied two groups of patients with adult acute myeloid leukemia... -
- CITED
-
- Close
- SHARE
-
- Close
- Long-term survival in a patient with acute promyelocytic leukemia with isolated meningeal relapse
-
Kim SH, Yun J, Kim HJ, Kim CK, Park SK, Hong DS
- KMID: 2252066
- Korean J Hematol.
- 2010 Sep;45(3):208-210.
- doi: 10.5045/kjh.2010.45.3.208
The meningeal involvement is rare in acute promyelocytic leukemia. We experienced a 39-year-old woman who achieved complete remission with all-trans retinoic acid, idarubicin and cytarabine therapy. Several months later, she... -
- CITED
-
- Close
- SHARE
-
- Close
- Induction Chemotherapy with N(4)-behenoyl-1-beta-D-arabinofuranosylcytosine, Idarubicin and 6-Thioguanine in Childhood Acute Myelogenous Leukemia
-
Jang PS, Yoo KH, Hong JY, Shin HY, Ahn HS
- KMID: 1979926
- Korean J Pediatr Hematol Oncol.
- 2000 Apr;7(1):72-81.
PURPOSE: Retrospective study was performed to evaluate the survivals, remission rate and complications of induction chemotherapy using N(4)-behenoyl-1-beta-D-arabinofuranosylcytosine (BH-AC), idarubicin and 6-thioguanine (6-TG) in newly diagnosed childhood acute... -
- CITED
-
- Close
- SHARE
-
- Close
- A Case of Hypercalcemia in the Blastic Phase of Chronic Myeloid Leukemia Associated with Elevated Parathyoid Hormone-related Protein
-
Lee SH, Mun BS, Kwak JY, Yim CY
- KMID: 1558503
- Korean J Med.
- 1998 Dec;55(6):1102-1106.
Hypercalcemia is a rare complication of chronic myelogenous leukemia, especially in the blastic phase. The incidence is below 5%. PTH-rP (parathyroid hormone- related protein) plays various roles in human physiology... -
- CITED
-
- Close
- SHARE
-
- Close
- A Case of Acute Panmyelosis with Myelofibrosis
-
Lee YJ, Park MR
- KMID: 2239048
- Korean J Lab Med.
- 2004 Aug;24(4):207-211.
We experienced a case of acute panmyelosis with myelofibrosis, one of the acute myeloblastic leukemia (AML) subtypes according to WHO classification. A 44 year old man presented with a laborious... -
- CITED
-
- Close
- SHARE
-
- Close
- Therapeutic Effect and Prognostic Analysis of Induction Chemotherapy with Idarubicin/BH-AC in Acute Myelogenous Leukemia
-
Lee JJ, Chung IJ, Yang DH, Cho SH, Yang TY, Park HC, Park MR, Kim HJ
- KMID: 2083409
- Korean J Hematol.
- 2000 May;35(2):109-116.
BACKGROUND: We have analyzed the outcome and prognostic factors for 61 patients with acute myelogenous leukemia (AML) who were treated with idarubicin(IDA)/N 4-behenoyl- 1-beta-D-arabinofuranosylcytosine(BH-AC) regimen at Chonnam National University Hospital... -
- CITED
-
- Close
- SHARE
-
- Close
- Successful Desensitization to Epirubicin in a Breast Cancer Patient with Doxorubicin Hypersensitivity
-
- KMID: 2234614
- Korean J Asthma Allergy Clin Immunol.
- 2009 Jun;29(2):127-131.
Doxorubicin, a chemotherapeutic agent of the anthracycline family, has commonly been used to treat a wide range of cancers including leukemia, Hodgkin's lymphoma, and cancers of the breast, uterus, ovary... -
- CITED
-
- Close
- SHARE
-
- Close
- Allogeneic Hematopoietic Stem Cell Transplantation Following Imatinib Plus Idarubicin and High-dose Cytarabine in Children with Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
-
An SA, Kim MH, Lee JW, Lee DH, Jang PS, Chung NG, Cho B, Jeong DC, Kim HK
- KMID: 2168944
- Clin Pediatr Hematol Oncol.
- 2010 Oct;17(2):163-173.
PURPOSE: To investigate the feasibility of imatinib-combined chemotherapy prior to allogeneic hematopoietic stem cell transplantation (HSCT) in childhood Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL), we treated five children with... -
- CITED
-
- Close
- SHARE
-
- Close
- Treatment of Refractory and Relapsed Acute Myeloid Leukemia with High-dose Cytarabine and Idarubicin
-
Lee HR, Park SH, Song SY, Park JO, Lee SI, Kim KH, Kim WS, Jung CW, Im YH, Kang WK, Park KC, Park GE, Kim SH, Lee HG
- KMID: 2143330
- Korean J Hematol.
- 2001 Nov;36(4):299-305.
BACKGROUND: The therapeutic outcome for refractory or relapsed acute myeloid leukemia (AML) is very poor; it is difficult to expect the long-term disease free survival in these patients. We evaluated... -
- CITED
-
- Close
- SHARE
-
- Close
- A Case of Acute Leukemia Remitted by Adding Cyclosporin-A Previously Failed with Induction Therapy
-
Park SB, Choe BK, Kim HS, Kang CM
- KMID: 2335503
- J Korean Pediatr Soc.
- 2000 Jul;43(7):988-992.
Clinical chemotherapy refractoriness is characterized by resistance to multiple drugs. Multidrug resistance(MDR) is caused by over-reactivity of a unidirectional drug efflux pump, transmembrane glycoprotein(P-glycoprotein), which is encoded by the MDR1 gene. P-glycoprotein leads... -
- CITED
-
- Close
- SHARE
-
- Close
- The First Korean Case of Moraxella osloensis Bacteremia in a Patient with Acute Myeloid Leukemia
-
Sung JY, Hong SK, Kim EC
- KMID: 1791931
- Ann Lab Med.
- 2014 May;34(3):256-258.
- doi: 10.3343/alm.2014.34.3.256
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
